ES2906192T3 - Biomarcadores para una enfermedad inflamatoria del intestino - Google Patents
Biomarcadores para una enfermedad inflamatoria del intestino Download PDFInfo
- Publication number
- ES2906192T3 ES2906192T3 ES17768220T ES17768220T ES2906192T3 ES 2906192 T3 ES2906192 T3 ES 2906192T3 ES 17768220 T ES17768220 T ES 17768220T ES 17768220 T ES17768220 T ES 17768220T ES 2906192 T3 ES2906192 T3 ES 2906192T3
- Authority
- ES
- Spain
- Prior art keywords
- genes
- individual
- risk
- ibd
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 233
- 239000000090 biomarker Substances 0.000 title description 3
- 230000014509 gene expression Effects 0.000 claims abstract description 260
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 247
- -1 nucleoside diphosphate Chemical class 0.000 claims abstract description 157
- 238000000034 method Methods 0.000 claims abstract description 129
- 210000004369 blood Anatomy 0.000 claims abstract description 118
- 239000008280 blood Substances 0.000 claims abstract description 118
- 102100022571 T cell receptor gamma constant 2 Human genes 0.000 claims abstract description 95
- 101000679307 Homo sapiens T cell receptor gamma constant 2 Proteins 0.000 claims abstract description 93
- 101001121539 Homo sapiens P2Y purinoceptor 14 Proteins 0.000 claims abstract description 80
- 102000018671 Lymphocyte Antigen 96 Human genes 0.000 claims abstract description 80
- 108010066789 Lymphocyte Antigen 96 Proteins 0.000 claims abstract description 80
- 102100025808 P2Y purinoceptor 14 Human genes 0.000 claims abstract description 80
- 102100028539 Guanylate-binding protein 5 Human genes 0.000 claims abstract description 79
- 101000679305 Homo sapiens T cell receptor gamma variable 3 Proteins 0.000 claims abstract description 79
- 102100038393 Granzyme H Human genes 0.000 claims abstract description 78
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims abstract description 78
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims abstract description 78
- 101000595347 Homo sapiens Peroxisomal coenzyme A diphosphatase NUDT7 Proteins 0.000 claims abstract description 77
- 102100036024 Peroxisomal coenzyme A diphosphatase NUDT7 Human genes 0.000 claims abstract description 77
- 101150032879 Fcrl5 gene Proteins 0.000 claims abstract description 76
- 101000784133 Homo sapiens Arrestin domain-containing protein 4 Proteins 0.000 claims abstract description 76
- 101001004750 Homo sapiens Galectin-related protein Proteins 0.000 claims abstract description 74
- 102100025614 Galectin-related protein Human genes 0.000 claims abstract description 73
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims abstract description 72
- 102100021038 Arrestin domain-containing protein 4 Human genes 0.000 claims abstract description 69
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 67
- 102100022591 T cell receptor gamma variable 3 Human genes 0.000 claims abstract description 60
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 230000003247 decreasing effect Effects 0.000 claims abstract description 18
- 102000006253 Interleukin-18 Receptor beta Subunit Human genes 0.000 claims abstract 14
- 108010058010 Interleukin-18 Receptor beta Subunit Proteins 0.000 claims abstract 14
- 108060005986 Granzyme Proteins 0.000 claims abstract 10
- 101710110795 Guanylate-binding protein 5 Proteins 0.000 claims abstract 10
- 102000014702 Haptoglobin Human genes 0.000 claims abstract 10
- 108050005077 Haptoglobin Proteins 0.000 claims abstract 10
- 102000001398 Granzyme Human genes 0.000 claims abstract 6
- 101710113220 Granzyme H Proteins 0.000 claims abstract 4
- 108091008874 T cell receptors Proteins 0.000 claims abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract 3
- 108010087819 Fc receptors Proteins 0.000 claims abstract 2
- 102000009109 Fc receptors Human genes 0.000 claims abstract 2
- 108091006027 G proteins Proteins 0.000 claims abstract 2
- 102000030782 GTP binding Human genes 0.000 claims abstract 2
- 108091000058 GTP-Binding Proteins 0.000 claims abstract 2
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims abstract 2
- 101710197212 Interferon-induced protein 44 Proteins 0.000 claims abstract 2
- 108090001090 Lectins Proteins 0.000 claims abstract 2
- 102000004856 Lectins Human genes 0.000 claims abstract 2
- 108091034135 Vault RNA Proteins 0.000 claims abstract 2
- 239000001177 diphosphate Substances 0.000 claims abstract 2
- 235000011180 diphosphates Nutrition 0.000 claims abstract 2
- 150000008195 galaktosides Chemical class 0.000 claims abstract 2
- 239000002523 lectin Substances 0.000 claims abstract 2
- 239000002777 nucleoside Substances 0.000 claims abstract 2
- 101001033000 Homo sapiens Granzyme H Proteins 0.000 claims description 74
- 238000011282 treatment Methods 0.000 claims description 64
- 238000011529 RT qPCR Methods 0.000 claims description 62
- 239000002299 complementary DNA Substances 0.000 claims description 46
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 30
- 238000007847 digital PCR Methods 0.000 claims description 27
- 208000011231 Crohn disease Diseases 0.000 claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 20
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 19
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 19
- 238000010195 expression analysis Methods 0.000 claims description 18
- 238000012163 sequencing technique Methods 0.000 claims description 17
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 16
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 13
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 13
- 238000010208 microarray analysis Methods 0.000 claims description 12
- 238000012049 whole transcriptome sequencing Methods 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 7
- 238000007477 logistic regression Methods 0.000 claims description 7
- 108700012920 TNF Proteins 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 238000012502 risk assessment Methods 0.000 claims description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 claims 5
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 abstract 2
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 abstract 2
- 201000008638 inflammatory bowel disease 1 Diseases 0.000 abstract 2
- 101710081120 T cell receptor gamma constant 2 Proteins 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 112
- 102100035010 Interleukin-18 receptor accessory protein Human genes 0.000 description 81
- 101001019615 Homo sapiens Interleukin-18 receptor accessory protein Proteins 0.000 description 80
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 75
- 201000010099 disease Diseases 0.000 description 74
- 101001033007 Homo sapiens Granzyme K Proteins 0.000 description 69
- 101001058850 Homo sapiens Guanylate-binding protein 5 Proteins 0.000 description 69
- 102100038395 Granzyme K Human genes 0.000 description 60
- 239000000047 product Substances 0.000 description 33
- 239000000126 substance Substances 0.000 description 26
- 238000012545 processing Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 13
- 238000002650 immunosuppressive therapy Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 238000002493 microarray Methods 0.000 description 11
- 238000011861 anti-inflammatory therapy Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 10
- 108010074051 C-Reactive Protein Proteins 0.000 description 9
- 102100032752 C-reactive protein Human genes 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 7
- 229960002170 azathioprine Drugs 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229960000598 infliximab Drugs 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000009115 maintenance therapy Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229960005205 prednisolone Drugs 0.000 description 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 101150076401 16 gene Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 238000002123 RNA extraction Methods 0.000 description 5
- 239000013614 RNA sample Substances 0.000 description 5
- 238000011366 aggressive therapy Methods 0.000 description 5
- 229960001334 corticosteroids Drugs 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 229960001428 mercaptopurine Drugs 0.000 description 5
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 5
- 229960004963 mesalazine Drugs 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000013517 stratification Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 4
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 238000005094 computer simulation Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000001325 log-rank test Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101150025032 13 gene Proteins 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 2
- 101150033839 4 gene Proteins 0.000 description 2
- 101150096316 5 gene Proteins 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000980965 Homo sapiens Protein CDV3 homolog Proteins 0.000 description 2
- 101150097005 IL18RAP gene Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100024449 Protein CDV3 homolog Human genes 0.000 description 2
- 238000013381 RNA quantification Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101150080446 TRGC2 gene Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003066 decision tree Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 238000011223 gene expression profiling Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000013643 reference control Substances 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 101150082072 14 gene Proteins 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 206010067671 Disease complication Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101001047006 Homo sapiens Histone acetyltransferase KAT2B Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000613575 Homo sapiens Paired box protein Pax-1 Proteins 0.000 description 1
- 101000613577 Homo sapiens Paired box protein Pax-2 Proteins 0.000 description 1
- 101000709106 Homo sapiens SMC5-SMC6 complex localization factor protein 1 Proteins 0.000 description 1
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 description 1
- 101000723759 Homo sapiens Zinc finger protein 26 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101150094988 IBD2 gene Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 101150084825 LGALSL gene Proteins 0.000 description 1
- 238000008149 MammaPrint Methods 0.000 description 1
- 101100286255 Mus musculus Id2 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000001759 Notch1 Receptor Human genes 0.000 description 1
- 108010029755 Notch1 Receptor Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102100040851 Paired box protein Pax-1 Human genes 0.000 description 1
- 102100040852 Paired box protein Pax-2 Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 102100032663 SMC5-SMC6 complex localization factor protein 1 Human genes 0.000 description 1
- 101150045544 TRGV3 gene Proteins 0.000 description 1
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 102100028392 Zinc finger protein 26 Human genes 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1611738.4A GB201611738D0 (en) | 2016-07-05 | 2016-07-05 | Biomarkers for inflammatory bowel disease |
| PCT/IB2017/000997 WO2018007872A1 (en) | 2016-07-05 | 2017-07-05 | Biomarkers for inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2906192T3 true ES2906192T3 (es) | 2022-04-13 |
Family
ID=56891052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17768220T Active ES2906192T3 (es) | 2016-07-05 | 2017-07-05 | Biomarcadores para una enfermedad inflamatoria del intestino |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11041206B2 (https=) |
| EP (1) | EP3481964B1 (https=) |
| JP (2) | JP7111630B2 (https=) |
| KR (1) | KR102352847B1 (https=) |
| CN (1) | CN109477145B (https=) |
| AU (1) | AU2017293417B2 (https=) |
| CA (1) | CA3029912A1 (https=) |
| DK (1) | DK3481964T3 (https=) |
| ES (1) | ES2906192T3 (https=) |
| GB (1) | GB201611738D0 (https=) |
| HU (1) | HUE058197T2 (https=) |
| LT (1) | LT3481964T (https=) |
| PL (1) | PL3481964T3 (https=) |
| PT (1) | PT3481964T (https=) |
| WO (1) | WO2018007872A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10515408B2 (en) | 2003-08-13 | 2019-12-24 | Bgc Partners, Inc. | Systems and methods for bid/offer liquidity spread trading |
| GB201611738D0 (en) | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
| US11978543B2 (en) | 2016-12-14 | 2024-05-07 | Astarte Medical Partners Inc. | System and methods for developing and using a microbiome-based action component |
| EP3554362A4 (en) * | 2016-12-14 | 2020-08-12 | Warren, Tracy | SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH |
| WO2020078993A1 (en) | 2018-10-18 | 2020-04-23 | T.J.Smith And Nephew,Limited | Tissue treatment device |
| GB201817052D0 (en) | 2018-10-19 | 2018-12-05 | Smith & Nephew | Tissue treatment device |
| CN110400603A (zh) * | 2019-07-23 | 2019-11-01 | 中国石油大学(华东) | 基于格局加权的ibd矩阵计算方法 |
| GB201912518D0 (en) | 2019-08-30 | 2019-10-16 | Cambridge Entpr Ltd | Inflammatory disease prognostics |
| GB202005867D0 (en) | 2020-04-22 | 2020-06-03 | Smith & Nephew | Tissue treatment device |
| GB202100527D0 (en) | 2021-01-15 | 2021-03-03 | Smith & Nephew | Systems and methods for managing operation of wound dressings or wound treatment devices |
| MX2023010694A (es) * | 2021-03-12 | 2023-11-23 | Janssen Biotech Inc | Métodos para predecir la respuesta al tratamiento en la colitis ulcerosa. |
| CN114517228A (zh) * | 2021-12-31 | 2022-05-20 | 青岛锐翌精准医学检验有限公司 | 炎症性肠病标志基因及其应用 |
| CN114645088B (zh) * | 2022-04-22 | 2023-12-15 | 广东省人民医院 | 克罗恩病进展风险相关评估基因集、试剂盒、应用和系统 |
| EP4606910A1 (en) * | 2024-02-21 | 2025-08-27 | Royal College of Surgeons in Ireland | Diagnostic and prognostic methods relating to ulcerative colitis |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0412301D0 (en) | 2004-06-02 | 2004-07-07 | Diagenic As | Product and method |
| US20070020660A1 (en) | 2005-06-06 | 2007-01-25 | Burczynski Michael E | Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases |
| GB0610949D0 (en) * | 2006-06-02 | 2006-07-12 | Glaxosmithkline Biolog Sa | Method |
| EP2261367A3 (en) * | 2007-11-29 | 2011-03-23 | Genentech, Inc. | Gene expression markers for inflammatory bowel disease |
| EP2268600A4 (en) * | 2008-04-02 | 2012-03-21 | Metaproteomics Llc | SUBSTITUTED 1,3-CYCLOPENTADION-ENHANCED ENDOTHELIAL IGNITION AND ENDOTHELIAL MONOCYTE INTERACTIONS |
| KR100985090B1 (ko) * | 2008-05-23 | 2010-10-04 | 한국과학기술연구원 | 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법 |
| WO2010084312A1 (en) | 2009-01-20 | 2010-07-29 | Cambridge Enterprise Limited | Methods for predicting autoimmune disease risk |
| EP2419532A1 (en) * | 2009-04-17 | 2012-02-22 | Université Libre de Bruxelles | Methods and tools for predicting the efficiency of anthracyclines in cancer |
| EP2272977A1 (en) | 2009-07-08 | 2011-01-12 | Universite Libre De Bruxelles | Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome |
| WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| WO2012115885A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| JP2014517279A (ja) | 2011-05-10 | 2014-07-17 | ネステク ソシエテ アノニム | 個別治療管理のための疾患活動性プロファイリングの方法 |
| US20130142809A1 (en) | 2011-11-23 | 2013-06-06 | Andrew A. Welcher | METHODS OF TREATMENT USING AN IFN gamma INHIBITOR |
| WO2013138497A1 (en) | 2012-03-13 | 2013-09-19 | Baylor Research Institute | Early detection of tuberculosis treatment response |
| JP2015532425A (ja) | 2012-10-05 | 2015-11-09 | ネステク ソシエテ アノニム | 粘膜治癒を予測及びモニタリングするための方法 |
| US20150315643A1 (en) | 2012-12-13 | 2015-11-05 | Baylor Research Institute | Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis |
| WO2014145631A1 (en) * | 2013-03-15 | 2014-09-18 | The Broad Institute, Inc. | Dendritic cell response gene expression, compositions of matters and methods of use thereof |
| WO2015120382A1 (en) * | 2014-02-07 | 2015-08-13 | The Johns Hopkins University | Predicting response to epigenetic drug therapy |
| KR20220065091A (ko) | 2014-03-27 | 2022-05-19 | 제넨테크, 인크. | 염증성 장 질환의 진단 및 치료 방법 |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| WO2016066288A1 (en) | 2014-10-28 | 2016-05-06 | Comprehensive Biomarker Center Gmbh | Mirnas as non-invasive biomarkers for inflammatory bowel disease |
| EP3262193A2 (en) * | 2015-02-26 | 2018-01-03 | The Broad Institute Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
| EP3286318A2 (en) | 2015-04-22 | 2018-02-28 | Mina Therapeutics Limited | Sarna compositions and methods of use |
| US20170003277A1 (en) * | 2015-07-01 | 2017-01-05 | Michael Hayden | Biological characterization of a glatiramer acetate related drug product using mammalian and human cells |
| GB201611738D0 (en) | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
-
2016
- 2016-07-05 GB GBGB1611738.4A patent/GB201611738D0/en not_active Ceased
-
2017
- 2017-07-05 LT LTEPPCT/IB2017/000997T patent/LT3481964T/lt unknown
- 2017-07-05 HU HUE17768220A patent/HUE058197T2/hu unknown
- 2017-07-05 ES ES17768220T patent/ES2906192T3/es active Active
- 2017-07-05 KR KR1020197002309A patent/KR102352847B1/ko not_active Expired - Fee Related
- 2017-07-05 JP JP2018565368A patent/JP7111630B2/ja not_active Expired - Fee Related
- 2017-07-05 CA CA3029912A patent/CA3029912A1/en active Pending
- 2017-07-05 DK DK17768220.0T patent/DK3481964T3/da active
- 2017-07-05 US US15/642,252 patent/US11041206B2/en not_active Expired - Fee Related
- 2017-07-05 PL PL17768220T patent/PL3481964T3/pl unknown
- 2017-07-05 PT PT177682200T patent/PT3481964T/pt unknown
- 2017-07-05 WO PCT/IB2017/000997 patent/WO2018007872A1/en not_active Ceased
- 2017-07-05 AU AU2017293417A patent/AU2017293417B2/en not_active Ceased
- 2017-07-05 CN CN201780041664.4A patent/CN109477145B/zh not_active Expired - Fee Related
- 2017-07-05 EP EP17768220.0A patent/EP3481964B1/en active Active
- 2017-07-17 US US15/651,746 patent/US10202651B2/en active Active
-
2018
- 2018-10-12 US US16/159,114 patent/US10640829B2/en active Active
-
2020
- 2020-08-13 JP JP2020136564A patent/JP2020198884A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB201611738D0 (en) | 2016-08-17 |
| US10202651B2 (en) | 2019-02-12 |
| WO2018007872A1 (en) | 2018-01-11 |
| US20180010187A1 (en) | 2018-01-11 |
| CA3029912A1 (en) | 2018-01-11 |
| JP2019527039A (ja) | 2019-09-26 |
| LT3481964T (lt) | 2022-04-11 |
| EP3481964B1 (en) | 2021-12-29 |
| PT3481964T (pt) | 2022-02-17 |
| JP7111630B2 (ja) | 2022-08-02 |
| US20190032140A1 (en) | 2019-01-31 |
| HUE058197T2 (hu) | 2022-07-28 |
| AU2017293417A1 (en) | 2019-02-21 |
| WO2018007872A9 (en) | 2018-03-15 |
| DK3481964T3 (da) | 2022-02-07 |
| KR102352847B1 (ko) | 2022-01-17 |
| US20180010189A1 (en) | 2018-01-11 |
| CN109477145A (zh) | 2019-03-15 |
| JP2020198884A (ja) | 2020-12-17 |
| US10640829B2 (en) | 2020-05-05 |
| CN109477145B (zh) | 2021-04-09 |
| NZ750396A (en) | 2020-12-18 |
| EP3481964A1 (en) | 2019-05-15 |
| PL3481964T3 (pl) | 2022-04-11 |
| US11041206B2 (en) | 2021-06-22 |
| KR20190025637A (ko) | 2019-03-11 |
| AU2017293417B2 (en) | 2019-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2906192T3 (es) | Biomarcadores para una enfermedad inflamatoria del intestino | |
| EP3129496B1 (en) | Molecular predictors of sepsis | |
| US10793911B2 (en) | Host DNA as a biomarker of Crohn's disease | |
| WO2019227015A1 (en) | Circulating rna signatures specific to preeclampsia | |
| US20240247315A1 (en) | Diagnosing inflammatory bowel diseases | |
| AU2017348369B2 (en) | Detection method | |
| HK40007518B (en) | Biomarkers for inflammatory bowel disease | |
| HK40003433A (en) | Biomarkers for inflammatory bowel disease | |
| HK40003433B (en) | Biomarkers for inflammatory bowel disease | |
| NZ750396B2 (en) | Biomarkers for inflammatory bowel disease | |
| RU2601132C1 (ru) | Набор синтетических олигонуклеотидов для диагностики болезни крона и неспецифического язвенного колита путем выявления маркерных участков бактериальной днк методом полимеразной цепной реакции |